# 1. Financial Performance ## A. Key Figures * **Revenue (Q4 FY26):** **₹1,084 Cr** (+35.3% YoY / +8.1% QoQ) * **Revenue (FY26):** **₹3,931 Cr** (+28.2% YoY) * **EBITDA (Q4 FY26):** **₹216 Cr** (+6.8% YoY / +5.9% QoQ) * **EBITDA Margin (Q4 FY26):** **19.9%** (vs 25.3% Q4 FY25) * **PAT (Q4 FY26):** **₹33 Cr** (vs ₹106 Cr Q4 FY25) * **FY26 EPS:** **₹6.03** (-37.2% YoY) * **Net Debt:** **~₹3,000 Cr** ## B. Revenue Growth * **New Unit Contribution:** Robust top-line momentum was significantly bolstered by newer units (operational <1 year), which contributed **₹224 Cr** to the quarterly total. * **Mature Market Dynamics:** In the core Telangana and Hyderabad cluster, revenue growth was primarily value-driven as inpatient volumes saw only modest single-digit growth. * **Consolidated Pressure:** While consolidated revenue showed strong double-digit growth, pre-Ind AS EBITDA faced a sharp contraction of over **32%**, highlighting transitional pressure from new assets. ## C. Margins & Profitability * **Margin Compression:** Significant year-on-year margin dilution and PAT decline reflect the heavy impact of commissioning new units and associated ramp-up costs. * **Resilient Core:** Mature units continue to demonstrate high operational efficiency, maintaining steady EBITDA margins between **28.5% and 29.5%** for both the quarter and full year. * **Profitability Outlook:** Management expects future margin expansion across all clusters; however, they conceded that FY26 performance in terms of ROE and ROCE fell short of initial expectations. ## D. Balance Sheet & Capital Allocation * **Deleveraging Strategy:** The company intends to utilize capital to retire **₹1,000 Cr** of debt, significantly strengthening the balance sheet against its current obligations. * **FY27 Financial Outlook:** Forward planning integrates QIP proceeds and CAPEX requirements to fund the ramp-up of currently loss-making facilities and complete ongoing projects. --- # 2. Capacity & Infrastructure ## A. Key Figures * **Kondapur Capacity:** **800 beds** total · **400 to 500 beds** Phase 1 * **Cluster Revenue (Q4):** **₹49 Cr** Mahadevapura · **₹47 Cr** Thane · **₹17 Cr** Electronic City (PES) * **Cluster EBITDA (Q4 Loss):** **₹25 Cr** Electronic City (PES) · **₹14 Cr** Mahadevapura · **₹5 Cr** Thane · **₹1 Cr** Nashik * **Projected EBITDA Growth:** **10%-12%** Telangana Cluster (FY27) ## B. Bed Expansion & Facility Commissioning * **Strategic Kondapur Transition:** The new flagship facility begins its transition in **June**, with a phased activation of its significant bed capacity to align with demand. * **Low-Cost Scaling:** Management will operationalize additional capacity once occupancy hits **60%**; this requires only incremental manpower as the primary capital expenditure is already finalized. * **Aggressive Multi-State Footprint:** FY25-26 marks a massive expansion phase with new units across **Hyderabad, Guntur, Maharashtra, Bangalore, and Kerala**, alongside specialized oncology and maternal care centers. ## C. Project CAPEX & Financing * **Capital Efficiency:** Major investment for the Kondapur facility is largely concluded, with a deferred requirement of **₹50 Cr to ₹75 Cr** pushed to **FY28/29** for final floor completions. * **Standardized Funding Mix:** Projects are typically structured with a **40:65 equity-to-debt ratio**, supplemented by minor **3% to 5%** doctor participation. ## D. Cluster Performance & Outlook * **Revenue Drivers vs. Gestation Losses:** Top-line momentum is fueled by new units in Bangalore and Maharashtra, though these clusters currently face narrowing losses as they ramp up operations. * **Karnataka Growth Trajectory:** Despite initial losses at the PES unit, the Mahadevapura unit is projected to scale monthly revenue to **₹25-30 Cr** within the next year. * **Telangana Volume Strategy:** Regional growth will be volume-led for the next **4-5 years** following the launch of Kompally and Kondapur, though EBITDA growth will see slight near-term moderation due to commissioning costs. --- # 3. Operational Metrics ## A. Key Figures * **FY '26 Growth:** **14%** ARPOB (+14%) · **11.4%** ARPP (+11.4%) · **15.4%** IP Volumes (+15.4%) · **25.4%** OP Volumes (+25.4%) * **Q4 FY '26 Growth:** **13.7%** ARPOB (+13.7%) · **14%** ARPP (+14%) · **17.9%** IP Volumes (+17.9%) · **30.1%** OP Volumes (+30.1%) * **Regional ARPOB:** **₹75,000** Bangalore Base · **₹26,000–27,000** Andhra Pradesh Run Rate * **Occupancy Rates:** **60.5%** Maharashtra Q4 Base · **~20%** Bengaluru Current ## B. Patient Volumes & Clinical Milestones * **Robust Volume Momentum:** Significant double-digit expansion in both inpatient and outpatient volumes for the full year and Q4, signaling strong market share capture. * **Clinical Excellence:** Achieved a major milestone with over **10,000** successful brain tumor surgeries, reinforcing the group’s tertiary care credentials. ## C. ARPOB & Occupancy Trends * **Regional Yield Dynamics:** Bangalore ARPOB reached a full-year peak of **₹85,000**, though management suggests a lower modeling base due to ALOS fluctuations and new program integration. * **Maharashtra Turnaround:** The region demonstrated a sharp occupancy ramp-up throughout the year, establishing a new sustainable floor above **60%**. * **Bengaluru Capacity Ramp:** Current low utilization in Bengaluru is projected to nearly double to **35-40%** of full capacity by the end of the next fiscal year. ## D. Talent Retention & Compensation * **Competitive Resilience:** Successfully defended medical talent in the hyper-competitive Hyderabad market despite significant new hospital commissions by rivals. * **Expansion Staffing:** Reporting positive traction in doctor recruitment across Karnataka and Kerala to support new department build-outs. * **Standardized Pay Model:** Employs a consistent, "healthy" compensation strategy across all geographies, replicating the proven incentive models from legacy markets. --- # 4. Strategic Initiatives ## A. Key Figures * **QIP Fundraising Target:** **INR 1,500 Cr** * **Current Gross Debt:** **INR 3,000+ Cr** * **Palakkad Revenue Potential:** **INR 12–15 Cr** per month ## B. QIP Fundraising & Capital Allocation * **Deleveraging Strategy:** Management plans to launch a QIP within **one to two months** to retire a significant portion of peak debt and optimize the capital structure. * **Cash Flow Management:** Fundraising proceeds will improve liquidity, allowing the company to fund back-ended greenfield project requirements through internal cash flows. * **Investor Alignment:** The shift toward a lower leverage target is a direct response to investor feedback regarding the balance sheet. ## C. M&A and Greenfield Pipeline * **Inorganic Growth:** Two near-term acquisitions are under evaluation for the next **two quarters**, alongside the integration of the Palakkad facility into the consolidated P&L. * **Regional Focus:** Greenfield development is concentrated in Karnataka, Kerala, and Tamil Nadu over a **24 to 36-month** horizon, while maintaining momentum in core Andhra Pradesh and Telangana markets. * **Project Lifecycle:** New builds are expected to take **three to five years** to reach full commissioning. ## D. Expansion Strategy * **Operational Consolidation:** Over the next **12 to 24 months**, the company will focus on bed additions and hospital consolidation to drive margin expansion. * **Growth Replication:** KIMS aims to mirror its previous five-year growth trajectory through a balanced mix of organic and inorganic expansion. * **Flexible Partnership Model:** The "doctor participation model" remains a strategic lever, permitting physicians to co-invest in expansion projects at their discretion. --- # 5. Regulatory & Execution Risks ## A. Key Figures * **Total EBITDA:** **₹216 Cr** for this quarter * **New Unit Revenue:** **₹597 Cr** Annual contribution from units <1 year old ## B. Empanelment Delays * **Regulatory Bottlenecks:** Industry-wide confusion following the **General Insurance Council (GIC)** common empanelment initiative has slowed ramp-ups in Nasik, Thane, and Bangalore. * **Execution Strategy:** Management is mitigating delays by staggering paperwork hospital-by-hospital and continuing individual provider negotiations while the broader regulatory landscape evolves. * **Cluster Progress:** Thane has secured **GIPSA** (part of **70%** of volume), while Nasik remains pending with major providers like **STAR** and **Medi Assist**. * **Operational Resilience:** Despite administrative delays, clinical talent acquisition and underlying patient demand in new markets remain consistent with established clusters. ## C. Margin Erosion * **Expansion Drag:** Profitability is temporarily depressed by rapid bed capacity expansion and the initial ramp-up phase of the **PES Hospital** in Karnataka. * **Transition Impact:** The Kondapur facility relocation is projected to incur a margin hit of **₹15 to ₹25 Cr**, mirroring historical trends seen during previous facility transitions. * **Growth Outlook:** Management expects margins to stabilize through consistent quarter-on-quarter growth within each cluster as new units mature. ## D. Macro Instability * **External Headwinds:** Fiscal year-end performance was pressured by global instability in the Gulf region, triggering national austerity measures and resource optimization mandates. --- # 6. Guidance & Outlook ## A. Key Figures * **Leverage Target:** **<1:2** Debt-to-EBITDA ratio * **Empanelment Timeline:** **6–9 months** Post-commissioning target ## B. EBITDA Recovery & Growth Trajectory * **Loss Mitigation:** Management expects a substantial reduction in EBITDA erosion as new units complete empanelments and scale operations. * **Long-term Outlook:** The company aims to sustain historical top-line and EBITDA growth rates over a **3 to 5-year** horizon, supported by a recent capital raise. * **Deleveraging Strategy:** Significant debt reduction is anticipated, fueled by QIP proceeds and improving operational cash flows to maintain a conservative balance sheet. ## C. Unit-Level Ramp-up Timelines * **Bangalore Cluster:** Full empanelment for the two Bangalore hospitals is slated for completion within the next **3 to 4 months**. * **Path to Profitability:** The Palakkad facility is projected to reach EBITDA break-even by **June or July**, while the Mahadevapuram unit is expected to turn EBITDA positive before **October 2026**. * **Operational Milestones:** The Thane facility has achieved neutral status despite temporary margin pressure from **new doctor additions**, and the PES (Electronic City) unit is on track for profitability by **March 2027**. * **Accelerated Gestation:** Despite heavy expansion expenditure impacting current year results, new units are trending toward profitability faster than initial management estimates.